Description: This session disscusses thel outlook of the Medicare program, current and longer-term reform proposals, and Medicare prescription drug proposals. From the Record of the Society of Actuaries, Volume 29, No. 2, Session 66

Description: This article is about the Balanced Budget Act of 1997. This Act revises the Medicare landscape by the creation of Part C - Medicare+Choice, Medical Savings Accounts, payment reforms.

Description: An article that provides an actuary's opinion of why health insurance reform will work and believes that Congress should use insurance reform as the cornerstone for successful legislation.

Description: Panelists at this session of the SOA 2000 Las Vegas Spring Meeting discuss the roles of the federal and state governments in regulating health care insurance, the potential overlaps of these jurisdictions, and how insurance companies, health plans, and providers are being affected.

Description: The author reviews the impact of health care exchanges becoming operational in 2014, and he offers ideas for efficient risk identification and ways to measure the results.

Description: Two Medicare risk funding provisions that were radically changed by the BBA of 1997 funding variations by geographic area and risk adjustment. Issue No. 36

Description: The chairperson reports on Health Section activities: papers by the joint workgroups with the AAA's Health Practice Council to inform the public and congressional staff, papers on capital requirements under proposed health care reform and on proposed taxing of Cadillac plans, new research on IBNR reserving methods and on measuring the quality and efficiency of health care delivery systems.

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.

Description: Article on the history of the Long Term Care Discussion Group, a Washington DC-based venue for discussing long-term care and related issues for over 20 years.

Description: Panel examines the actuarial, business, clinical, and ethical issues attached to physician-owned health plans in which the physicians are both providers and investors. From the Record of the Society of Actuaries, Vol. 24, No. 3.